Merck Seeks EUA for COVID-19 Treatment
Molnupiravir reduced the risk of hospitalization or death by about 50%.
Merck has submitted an Emergency Use Authorization (EUA) application to the FDA for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
The submission is based on positive results from a planned interim analysis from the phase 3 MOVe-OUT clinical trial. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by about 50%. The incidence of drug-related adverse events was 12% in the molnupiravir group versus 11% in the placebo cohort, and fewer subjects in the molnupiravir group discontinued therapy due to an adverse event compared with the placebo group.
Related:Data Show Merck’s Oral Antiviral Cuts Risk of Death from COVID-19 in Half
Molnupiravir was invented at Drug Innovations at Emory, a not-for-profit biotechnology company wholly owned by Emory University. Molnupiravir is being developed by Merck in collaboration with Ridgeback Biotherapeutics.
The companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 4th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 4th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
